ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Coronavirus

Peru volunteer in Sinopharm COVID vaccine trial dies of pneumonia

Participant received a placebo, says university involved in study

A coronavirus vaccine candidate from China National Biotec Group, a unit of state-owned pharmaceutical giant China National Pharmaceutical Group (Sinopharm), is displayed at a trade fair in Beijing in September 2020.   © Reuters

LIMA (Reuters) -- A volunteer in the local Peruvian trial of a coronavirus vaccine produced by China's Sinopharm Group Co Ltd has died from COVID-19-related pneumonia, the university carrying out the trial said on Tuesday.

Cayetano Heredia University, which is involved with the study, said on the instructions of the Peruvian health regulator it had unblinded the volunteer's participation in the trial and determined she had received the placebo rather than the vaccine.

"It is important to stipulate that the death of the participant is not related to the vaccine since she received the placebo, and we will therefore report to the relevant regulatory and ethics bodies and maintain the course of this phase three study," the university said in a statement.

German Malaga, chief researcher at the Cayetano Heredia University, told Reuters by phone that the deceased volunteer had suffered from diabetes.

Malaga said the trial investigators had so far issued two doses of either the vaccine or placebo to 12,000 volunteers and were now following their responses.

"It is developing without any setbacks. These things can happen, COVID is a disease that causes deaths," he said.

"Our message to the volunteers is to take care of themselves because we don't know if they have the vaccine or the placebo," he added.

The university said in its statement that the volunteer had received "all the necessary care to treat this disease and her complications" and was "fighting for her life" for more than a week.

"It is a painful loss for which we extend our condolences to her family," the statement added.

In December, Peru temporarily suspended trials of the Sinopharm COVID-19 vaccine due to a "serious adverse event" that occurred with a volunteer in the study.

In Brazil, clinical trials of China's Sinovac COVID-19 vaccine were suspended before being allowed to resume late last year due to a study subject's death that was registered in Sao Paulo as a suicide.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends October 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to Nikkei Asia has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more